A Gavi-funded global emergency stockpile of Ebola vaccines will be accessible to all countries following a procurement process concluded by UNICEF

The United States has approved US$ 4 billion for Gavi, the Vaccine Alliance to ensure lower-income economies have equitable access to safe and effective COVID-19 vaccines on the same urgent timeline as wealthier countries.

COVAX now has agreements in place to access nearly two billion doses of several promising vaccine candidates, and laid the groundwork for further doses to be secured through contributions from donors.

Gavi Board approves more than US$ 600 million in new funding to help accelerate efforts to reach ‘zero-dose’ and under-immunised children in the face of the COVID-19 pandemic.

High-risk and vulnerable groups and healthcare workers first in line for successful vaccine.

Memorandum of understanding signed today will strengthen collaboration on vaccination efforts and related health services for migrants and forcibly displaced persons across the world

Geneva, 24 November 2020 – Gavi, the Vaccine Alliance, as co-lead of COVAX and administrator of the COVAX Facility, welcomes the release of interim efficacy data for the AstraZeneca/Oxford COVID-19 vaccine candidate.

The COVAX AMC Engagement Group, composed of Gavi COVAX AMC participants, donors, and other stakeholders, forms a key component of Facility governance.

The European Commission, France, Spain, The Republic of Korea and the Bill & Melinda Gates Foundation pledge US$ 360 million to Gavi’s COVID-19 Vaccines Advance Market Commitment (COVAX AMC)

The COVAX Shareholders Council, composed of all self-financing participants, forms a key component of Facility governance.

As part of the global response to the COVID-19 pandemic, COVAX – the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, co-led by Gavi, CEPI, and the WHO – welcomes the appointment of civil society organisation representatives to…

Gavi, the Vaccine Alliance announced today that it had signed a Statement of Intent with Sanofi and GSK to provide 200 million doses of the companies’ adjuvanted recombinant protein COVID-19 vaccine to the COVAX Facility.

Last updated: 11 Jun 2020

Subscribe to our newsletter